Drug Trial Radar · NCT05492500
A Study of Ponsegromab in People With Heart Failure
Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
455
Actual
Start
Sep 26, 2022
Primary completion
Mar 5, 2025
Study completion Mar 5, 2025
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- The TIMI Study Group
- First posted
- Aug 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Supportive care
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this clinical trial is to compare the effects of study medicine (Ponsegromab/PF-06946860) with a placebo (an injection that looks like the study medicine but does not contain the active medicine) to find out if the study medicine is better than the placebo (an injection that looks like the study medicine but does not contain the active medicine) for treatment of symptoms related to heart failure. Participants will not know which treatment group they are assigned to. Most participants in this study will receive the study medicine or placebo by shots under the skin every four weeks. People may be able to participate in this study if they have heart failure. Participants will take part in this study for about 9 months. During this time participants will visit the study clinic once a month. A separate PK cohort within this clinical trial will receive open-label study medicine (Ponsegromab/PF-06946860) only. Participants in this open-label, PK cohort will not receive placebo. These participants will receive the study medicine by shots under the skin every four weeks. People may be able to participate in this study cohort if they also have heart failure. Participants will take part in the open-label, PK cohort for about 7 months.
Conditions
- Heart Failure
Interventions
Main cohort (Cohort A): Ponsegromab low doseDrug
Ponsegromab low dose subcutaneous injection
Main cohort (Cohort A): Ponsegromab medium doseDrug
Ponsegromab medium dose subcutaneous injection
Main cohort (Cohort A): ponsegromab high doseDrug
Ponsegromab high dose subcutaneous injection
Main cohort (Cohort A): Matched placeboOther
Matched placebo subcutaneous injection
Open-label, PK Cohort (Cohort B): ponsegromab low doseDrug
ponsegromab low dose subcutaneous injection
Open-label, PK Cohort (Cohort B): ponsegromab medium doseDrug
Ponsegromab medium dose subcutaneous injection
Open-label, PK Cohort (Cohort B): ponsegromab high doseDrug
Ponsegromab high dose subcutaneous injection
Optional Cohort C: Ponsegromab low doseDrug
Ponsegromab low dose subcutaneous injection
Optional Cohort C: Matched placeboOther
Matched placebo subcutaneous injection
Optional Cohort D: Ponsegromab high doseDrug
Ponsegromab high dose subcutaneous injection
Optional Cohort D: Matched placeboOther
Matched placebo subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ)-23 - Clinical Summary Score (CSS) at Week 22: Cohort A, Ponsegromab 300 mg Versus PlaceboTime frame: Baseline [the last measurement on study Day 1], Week 22
Locations
122 sites in 11 countries. Site status is shown where the registry gives one.
Eastern shore Research Institute LLC
Fairhope, Alabama
Keck Medical Center of USC
Los Angeles, California
MedStar Washington Hospital Center
Washington D.C., District of Columbia
Emory University School of Medicine-Grady Campus
Atlanta, Georgia
Chicago Medical Research
Hazel Crest, Illinois
Reid Physician Associates
Richmond, Indiana
Brigham and Women's Hospital
Boston, Massachusetts
Henry Ford Hospital
Detroit, Michigan
Traverse Heart & Vascular
Traverse City, Michigan
M Health Fairview Clinics and Surgery Center
Minneapolis, Minnesota
M Health Fairview University of Minnesota Investigational Drug Services
Minneapolis, Minnesota
M Health Fairview University of Minnesota Medical Center-East Bank
Minneapolis, Minnesota
University of Minnesota/Lillehei Clinical Research Unit
Minneapolis, Minnesota
Saint Luke's Hospital of Kansas City
Kansas City, Missouri
Washington University in St. Louis Center for Outpatient Health (COH)
St Louis, Missouri
Washington University in St. Louis Center for Advanced Medicine (CAM)
St Louis, Missouri
Washington University School of Medicine
St Louis, Missouri
Holy Name Medical Center
Teaneck, New Jersey
University of North Carolina Medical Center
Chapel Hill, North Carolina
Clinical and Translational Research Center
Chapel Hill, North Carolina
South Oklahoma Heart Research, LLC
Oklahoma City, Oklahoma
Texas Health Heart & Vascular Specialist (THHVS) #18760
Dallas, Texas
Concord Repatriation General Hospital
Concord, New South Wales, Australia
Core Research Group
Brisbane, Queensland, Australia
The Prince Charles Hospital
Chermside, Queensland, Australia
Lyell McEwin Hospital
Elizabeth Vale, South Australia, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Fraser Clinical Trials Inc
New Westminster, British Columbia, Canada
QEII Health Sciences Centre - Victoria General Site
Halifax, Nova Scotia, Canada
Saul Vizel Professional Medicine Corporation dba Vizel Cardiac Research
Cambridge, Ontario, Canada
University Hospital - London Health Sciences Centre
London, Ontario, Canada
North York Diagnostic and Cardiac Centre
North York, Ontario, Canada
Private Practice - Dr. James Cha
Oshawa, Ontario, Canada
Kawartha Cardiology Clinical Trials
Peterborough, Ontario, Canada
Corcare
Toronto, Ontario, Canada
Unity Health Toronto, St. Michael's Hospital
Toronto, Ontario, Canada
Community Care Building
Winchester, Ontario, Canada
Winchester District Memorial Hospital
Winchester, Ontario, Canada
Institut de Cardiologie de Montreal
Montreal, Quebec, Canada
Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, Canada
Showing 40 of 122 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.